Pharma

Takeaways from OIS@ASCRS 2018

15 Things We Learned at OIS@ASCRS

By Rich Kirkner | April 20, 2018

Here are 15 takeaways from last week’s OIS@ASCRS 2018. Barry Cheskin of PowerVision reported on a pilot study of 27 patients who had the FluidVision…

Read More
41 Things On Tap at OIS@ASCRS

41 Things On Tap at OIS@ASCRS

By Rich Kirkner | April 4, 2018

There are 41 different sessions, panels, and presentations happening at OIS@ASCRS 2018 – including five different breakout sessions on everything from dry eye to emerging…

Read More
Can ODs Take Over Ocular Surface Disease?

Will ODs Take Over Ocular Surface Disease Treatment?

By Tom Salemi | March 9, 2018

Over the past decade, the treatment of ocular surface conditions such as dry eye and meibomian gland dysfunction (MGD) has evolved from “pats on the…

Read More
FILLY Results Keep Apellis on Track

FILLY Results Keep Apellis on Track

By Rich Kirkner | February 28, 2018

Apellis Pharmaceuticals‘ plans to begin the Phase III trial of its complement C3 inhibitor candidate APL-2 for treatment of geographic atrophy received a boost last…

Read More
Who Will be Making News Next Month?

What’s Happening in the Month Ahead: February 2018

By Rich Kirkner | February 6, 2018

Clinical Trial Updates Due at Angiogenesis Meeting Investigators will present a host of updates on clinical trials in retina at Angiogenesis, Exudation and Degeneration 2018…

Read More
Allergan Ready for a Future of Generic Competitors

Allergan Ready for a Future of Generic Competitors

By Steve Lenier | January 25, 2018

At the 36th annual JP Morgan Healthcare Conference in San Francisco, Allergan CEO Brent Saunders said a disconnect exists between the company’s 2017 results and…

Read More
Foundation Fighting Blindness in Fight to Preserve Orphan Drug Tax Credit

Foundation Fighting Blindness in Fight to Preserve Orphan Drug Tax Credit

By Rich Kirkner | December 13, 2017

As House and Senate negotiators reportedly reached agreement on a tax-reform package, the fate of the orphan drug tax credit remained uncertain. Advocates have been…

Read More
Why The “Digital Natives” Are Restless

Masters of Industry: Digitization, Millennials, and the Future of Device and Pharma

By Rich Kirkner | November 29, 2017

The forces driving ophthalmic innovation are digitization and demographics, namely in the emergence of millennials, and how the major players in ophthalmology respond to those…

Read More
Integrins Gain Traction in Ophthalmology

With Integrins, Necessity Really is the Mother of all Invention

By Michelle Dalton | September 14, 2017

Stopping growth factors that create damage in the eye has proven lucrative. Lucentis (ranibizumab, Roche/Genentech) achieved sales of $1.8 billion in 2016 outside the US…

Read More
Double Shot Gives Spark Therapeutics a Jolt

Double Shot Gives Spark Therapeutics a Jolt

By Rich Kirkner | July 26, 2017

Spark Therapeutics is riding a double shot of positive news about its gene therapy treatment for RPE65-mediated inherited retinal disorders that’s given its stock a…

Read More
Inotek May Be for Sale, But Who Will Buy?

Inotek May Be for Sale, But Who Will Buy?

By Steve Lenier | July 19, 2017

With another failed trial of its glaucoma candidate trabodenoson in hand, Inotek Pharmaceuticals Corp. is pondering options that could include selling the company, but finding…

Read More
AGTC Makes Moves with Cash in Hand

AGTC Makes Moves with Cash in Hand

By Rich Kirkner | July 11, 2017

As Applied Genetic Technologies Corporation (AGTC) heads into the summer with encouraging results for two of its lead candidates using the adeno-associated virus-based gene technology…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.